BLACK DIAMOND THERAPEUTICS I's ticker is BDTX and the CUSIP is 09203E105. A total of 75 filers reported holding BLACK DIAMOND THERAPEUTICS I in Q2 2023. The put-call ratio across all filers is 0.18 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $69,323 | +4.1% | 36,679 | -0.9% | 0.00% | – |
| Q4 2022 | $66,611 | -28.4% | 37,006 | -32.7% | 0.00% | – |
| Q3 2022 | $93,000 | -62.9% | 54,978 | -46.2% | 0.00% | – |
| Q2 2022 | $251,000 | -50.0% | 102,126 | -43.6% | 0.00% | – |
| Q1 2022 | $502,000 | -28.7% | 181,097 | +37.0% | 0.00% | – |
| Q4 2021 | $704,000 | -34.0% | 132,156 | +4.8% | 0.00% | – |
| Q3 2021 | $1,067,000 | -54.7% | 126,106 | -34.8% | 0.00% | -100.0% |
| Q2 2021 | $2,358,000 | +15.0% | 193,462 | +128.9% | 0.00% | 0.0% |
| Q1 2021 | $2,051,000 | -11.4% | 84,528 | +17.0% | 0.00% | 0.0% |
| Q4 2020 | $2,316,000 | +873.1% | 72,256 | +817.9% | 0.00% | – |
| Q3 2020 | $238,000 | -66.9% | 7,872 | -53.7% | 0.00% | – |
| Q2 2020 | $718,000 | -68.0% | 17,017 | -81.1% | 0.00% | -100.0% |
| Q1 2020 | $2,246,000 | – | 90,037 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Boxer Capital, LLC | 2,014,858 | $17,046,000 | 0.60% |
| NEA Management Company, LLC | 3,449,845 | $29,186,000 | 0.35% |
| MPM BioImpact LLC | 248,506 | $2,102,000 | 0.33% |
| Artal Group S.A. | 1,646,517 | $13,930,000 | 0.31% |
| RA Capital Management | 2,589,904 | $21,911,000 | 0.30% |
| Bellevue Group AG | 3,463,000 | $29,297,000 | 0.30% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 760,128 | $6,431,000 | 0.13% |
| Ikarian Capital, LLC | 150,484 | $1,272,000 | 0.09% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 44,000 | $371,000 | 0.09% |
| Virtus ETF Advisers LLC | 16,600 | $140,000 | 0.06% |